The human leukocyte antigen (HLA) complex is the human counterpart to the major histocompatibility complex (MHC). The HLA genes are encoded in a cluster on the short arm of chromosome 6, which encodes the family of HLA antigens. In humans, the MHC is divided into Classes I, II, and III. The A, B, C, E, F, and G genes belong to MHC Class I, whereas the 6 D genes belong to Class II. Most clinically relevant HLA molecules locate in the Class I and II regions. The Class III includes genes coding a few secreted proteins with immune functions, including inflammation-related molecules such as tumor necrosis factor-α (TNF-α).

To date, accumulative evidence suggests that multiple genes in the HLA regions are likely to play an important role in development of cancer and immunity disorders. However, the biological mechanisms of the HLA associations remain to be elucidated. Multiple whole genome association studies either confirmed signals in the HLA regions that were reported previously or established new location for nasopharyngeal carcinoma (NPC) which was not reported earlier \[e.g., the HLA-F region reported in a genome-wide association (GWA) study in a Taiwanese population[@b1]\]. Despite the confirmed associations, there is little understanding of the relationship between the genetic variants discovered in the 6p21.3 region and of whether these "significant" variants work independently or additively[@b1],[@b2]. Although most previous studies are limited by both the resolution of the genetic map and sample size, there are obvious lessons to be learned from statistical signals detected by multiple GWA studies while limiting disease types by infections tumors or immune disorders.

We recently conducted a survey of all GWA studies reported genome-wide significant findings in the HLA region and concluded that diseases such as cancer and immune disorders are more likely to be associated with genetic variants located in the HLA regions than other diseases. In [Figures 1](#cjc-30-04-226-g001){ref-type="fig"} and [2](#cjc-30-04-226-g002){ref-type="fig"}, we highlighted the peaks of all GWA studies conducted between 2008 and 2010 on immunity disorders and infectious tumors, respectively. The main goal of this mini-review is to discuss the potential relationships of these findings generated from the large-scale GWA studies of infectious tumors and immunity disorders[@b1]--[@b44].

We also reviewed all the GWA peaks occurred in the HLA regions across several types of cancers. As shown in [Figure 2](#cjc-30-04-226-g002){ref-type="fig"}, NPC, variants associated with Hodgkin\'s disease, follicular lymphoma, and chronic lymphocytic leukemia (CLL) revealed in a region of less than 0.25 megabase.

![Twelve immune diseases and disorders included in all genome-wide association (GWA) studies conducted between 2008 and 2010. The *Y*-axis indicates the names of the genes, and *X*-axis indicates the genomic locations. The dark vertical bars indicate the location of the HLA-genes in relations to the association signals. The diseases are expressed using different shapes. Different studies are labeled with colors. For instance, celiac disease is expressed using a red triangle, lupus is expressed using a purple dot, and leprosy is expressed using a blue triangle.](cjc-30-04-226-g001){#cjc-30-04-226-g001}

![Twelve infectious tumors included in all GWA studies conducted between 2008 and 2010. The *Y*-axis indicates the names of the genes, and *X*-axis indicates the genomic locations. The dark vertical bars indicate the location of the HLA-genes in relations to the association signals. Eight diseases are expressed using different shapes and separate studies in the same disease are labeled using colors.](cjc-30-04-226-g002){#cjc-30-04-226-g002}

Results indicated that a total of 12 GWA studies of immune disorders revealed positive association signals in 6p21.3 regions which include leprosy, psoriasis, rheumatoid arthritis (RA), type I diabetes, NPC, celiac disease (CD), systemic lupus erythematosus (SLE), inflammatory disease (IBD), multiple sclerosis (MS), immunoglobulin deficiency, and HIV infection. Some of these findings can be implied clinically. For instance, the HLA gene testing is now recommended for CD patients, as most patients with CD carry the HLA-DQ alleles (shown as a red triangle in [Figure 1](#cjc-30-04-226-g001){ref-type="fig"}) associated with CD. On the other hand, the presence of CD symptoms alone may not perfectly predict the odds of an individual which might have CD. Therefore, individuals with potential CD in high risk groups, such as first-degree relatives of CD patients, or those with other autoimmune diseases, could consider genetic diagnostic testing. As indicated in [Figure 1](#cjc-30-04-226-g001){ref-type="fig"}, the variants associated with SLE, RA, IBD, and type I diabetes locate relatively close to each other, which further justify the rationale of considering other immune disorders in proband\'s relatives while selecting an individual for genetic testing.

To deepen our understanding of HLA-related associations, a natural further step would be to sequence the genomic region that is in close proximity of the significantly associated single-nucleotide polymorphisms (SNPs) revealed by GWA studies. The cost of whole genome sequencing (WGS) may soon become affordable and the WGS approach will enable the discovery of both common and rare variants in the genome. The WGS approach will provide opportunities to analyze the genetic contribution made by rare variants and less common variants or by joint effect and to analyze the common and rare variants in the near future. Before the WGS data become available, some investigators might be interested in conducting meta-analysis using disease phenotypes that can be defined as a "cluster of phenotypes". For instance, one may wish to include infectious tumors such as NPC, Hodgkin\'s disease as well as some types of non-Hodgkin\'s lymphomas as a "cluster" because they share a known viral etiology related to the infection of Epstein-Barr virus (EBV). Because nearly all patients with NPC are EBV-positive, and some patients with lymphoma tend to be EBV-positive, it can be hypothesized that individuals who carry specific HLA alleles or haplotypes with weakened ability to present EBV antigens to the immune system might have higher likelihood to developing NPC, and Hodgkin\'s or some types of non-Hodgkin\'s lymphoma[@b45]--[@b55].

Needless to say, the "clustered" meta-analysis should be carried out with caution and need to take population structure into account. Further, researchers can combine data on diseases such as lupus, inflammatory bowl diseases, psoriasis and celiac diseases to conduct a meta-analysis to test whether these immune disorders share a common genetic etiology. Meanwhile, we are holding hope for the gains from upcoming WGS studies. WGS results are likely to allow us to construct more reliable haplotypes in the HLA region and, therefore, increase the power of identifying genetic factors for immune-related diseases or infectious tumors. More importantly, the high resolution of the WGS approach may allow us to test whether the genetic variants in closely related regions carry independent or additive effects. Novel findings are expected to have significant implications for functional studies and for sequencing-based application in personalized medicine.

We would also like to note that 5 disorders listed in [Figures 1](#cjc-30-04-226-g001){ref-type="fig"} and [2](#cjc-30-04-226-g002){ref-type="fig"} are related to EBV infection. EBV is a ubiquitous virus which infects 90% of the human adult population. It is now believed that at least 90% of EBV infections are transmitted orally through exchange of infected saliva. Although many tissues and organs of the body may become infected with EBV, the primary ones include the epithelial cells of the nasopharynx and the B lymphocytes of the immune system. It is well known that EBV is an important risk factor for NPC. And EBV has long been the suspected cause of Hodgkin\'s disease. More recently, EBV has been implicated in autoimmune diseases such as RA, SLE, and MS. This survey indicates that findings from GWA studies on the above mentioned diseases revealed multiple potential genetic variants in the 6p21.3 region although among these signals, some are in close proximity and others are farther apart. The current finding is not a proof for a common root for development of immune diseases but is suggestive for testing a hypothesis of a common etiology of different disorders. We will certainly make a great effort in these highlighted regions by linking infections tumors and/or immune disorders into one cluster. This effort may lead to more comprehensive understanding of the biological nature of infectious tumor and immune disorders.

Finally, we would like to highlight an impressive study of multinational consortium in which researchers identified more than one million genetic variants in DNA samples from people with HIV, some are considered "super controls" and some are not. The super controls are HIV-positive, but have not taken medicine and have not developed AIDs. The researchers reported more than 300 variations reside in the HLA regions (due to the limited space in the graph, only a portion of 300 signals were included in [Figure 1](#cjc-30-04-226-g001){ref-type="fig"}, and more details are referred to the original manuscript) that differed substantially between the super controls and the normal controls. This observation suggests that these variations can change the means that the human immune system recognizes HIV-infected cells via several relevant HLA proteins. This finding speaks for the need of a careful examination of the role of HLA for immune diseases, and also suggests identifying relevant HLA genes which can function either jointly or independently and demonstrating the functional role of HLA genes in recognizing virus-infected cells.
